If you read 10-k, they show additional $5m in buyback. So far ( to date) they purchased less than $4m .. should move higher especially if they can increase sales and or M&A
LJPC) today announced that it will commence a share repurchase plan for up to $10 million of the Company’s common stock. Repurchases may be made from time to time at the Company’s discretion. The plan has no time limit and can be discontinued at any time.
It’s happening, higher base
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress
Good to know! I looked at Earnings Whisper and it said 15th go figure
Not much movement from it though
They reported this morning.... beat on revenue. More cost reductions. Have over $40 million in cash now. Looking good on the balance sheet and growing revenue every quarter
March 15th before the open
Is/Are today the Financials are released Q4, Annual? Any guidance, Conf call please!!
Tang has a lot going on with different tickets. I assume he has some grand plan to bring it all together. Maybe he’s not ready yet to share. I’m kinda a believer that he has a chance to bring significant value here
Totally agree! Would be great if we could get some sell side analysts involved! Communication from MgMt ( conferences, ‘fire side’ chats helpful
Maybe he will. Never know. They’re going to eventually have to start addressing investors more. I’ve been very pleased with my returns here but I believe this can really break out higher
Agreed! Good volumes last couple days, Blackrock filing 13g, etc..Just wish new CEO would do Q&A after EPS release next month
Maybe w/ just Gia, I’m thinking same template like Paion( both
Giapreza and Xerava Together)..we shall see soon, hopefully sales gained some traction here in the states??
Been a slow ramp up w/ Just Gia
Already exists doesn’t it? Everest medicine ..... should have an update on that anytime.
Also interesting it had such a large volume of shorts on that spike on the news on Jan 12th. Yet it’s held gains and is going back up on relatively low volume. Could squeeze them
Or maybe Asian licensing agreement like recent EU collaboration?
International expansion now that we have a real CEO
Agreed! Finally starting to build out business internationally!
Tang owns 30+%, low floater
Shhhh, she’s a blessing on everything she touches lately, lol ?? ?? any where from 35-200% higher once the “Charts’ are posted ??
Swing and a miss on that assessment?
Same here Star, almost picked off 2000 more at $4.10 as news hit , missed it ! Lol
I love this lady CT??
Yes indeed, I have been loaded since the Covid crash and ready for take off back to $20's
Finally management exists and working for US!!
It has to be some kind of merger so the Company closed the headquarter, no employees and Auctioned all the equipments. We may get an updates any day.
Yeah I don’t disagree. Public company’s are supposed to be more transparent than this. But I’m sure there’s something big in the works behind the curtains here and it will be revealed, eventually.
that's not how you run a publicly traded company (especially mkt caps of $100mm+).. that's why we have 0 sell/buy side analysts..we have a great story to tell, but it's falling on deaf ears, imho..nonetheless, somethings up:)
I honestly don’t care how transparent they are. I’m sure they’ll share news when they have it. No way Tang is putting that much on the line and buying up the float for nothing. Something is up here for sure.
agreed! just wish they were more shareholder friendly but perhaps with Edwards as new CEO, they will hold qtrly conf calls. the previous CFO and i would speak occasionally, but of course nothing 'insider' based... they did have high hopes on the malaria drug( more for voucher reasons-could have been worth 100mm+) but that went to competing private company.. maybe Kevin and Edwards can buy them, lol.. glta
Has to be something good in the works here with all this insider buying. The tetraphase buyout looks promising as well. Interesting news with them letting the contract for their facility expire. Could be a buyout or something else like a merger etc. I’m in this heavily, I see too much potential.
$LJPC La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2019
GlobeNewswire GlobeNewswire•March 2, 2020
La Jolla Pharmaceutical Company, a biopharmaceutical company, engages in the research and development of pharmaceutical products in the United States. Its principal product in development is Riquent, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. Riquent is in Phase III clinical trial. The company also develops small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders. La Jolla Pharmaceutical Company was founded in 1989 and is based in San Diego, California.
Riquent (abetimus sodium) is a synthetic oligonucleotide conjugate composed of 4 identical strands of dsDNA (20BP in length) that are linked through a triethyleneglycol-based platform. It binds anti-dsDNA Ab and the complex is cleared via the immune system, thus ridding the body of one of the primary pathogenic antibody associated with lupus.
Lupus nephritis is a serious and potentially fatal orphan disease treated primarily by nephrologists and rheumatologists. Currently, there are no products specifically approved to treat lupus renal disease.
La Jolla Pharmaceutical is investigating Riquent for the treatment of lupus renal disease by preventing or delaying renal flares, a leading cause of sickness and death in lupus patients, and improving proteinuria. Proteinuria is an indicator of abnormal renal function. Riquent has been well tolerated in all 14 clinical trials, with no overall difference in the adverse event profiles for Riquent-treated patients compared with placebo-treated patients. Riquent specifically reduces circulating levels of anti-dsDNA antibodies and is also designed to specifically suppress the B cells that make these antibodies. Decreases in these antibodies are believed to be associated with a decreased risk of renal flare. Although clinical benefit has not yet been proven, Riquent treatment has significantly reduced these antibody levels in all clinical trials in which they were measured.
3 Month Chart